EX-10.19




 Exhibit 10.19 

 

This amendment corrects a technical error where the reference to Section 4.4 as set forth below was incorrectly 4.2 in
the original document. 

 CONFIDENTIALTREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

AMENDMENT NO. 1 
 TO THE
EXCLUSIVE LICENSE AGREEMENT 
 This Amendment No. 1 to the Exclusive License Agreement (the “Amendment”) is made
as of this 8th day of August, 2000, by and between Introgen Therapeutics, Inc., a Texas corporation having its principal place of business at 301 Congress Avenue, Suite 1850, Austin, Texas 78701
(“Introgen”), Corixa Corporation, a Delaware corporation having its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104 (the “Company”), and Chinook Corporation, a Delaware
corporation and a wholly-owned subsidiary of the Company “Chinook,” and collectively with the Company, “Corixa”). 

RECITALS 
 WHEREAS, the
parties hereto have entered into that certain Exclusive License Agreement, effective as of July 19, 1999 (the “Agreement”); and 

WHEREAS, the parties desire to amend the Agreement to correct a provision thereof to milestone payments; 

NOW, THEREFORE, the parties hereby agree to amend the Agreement as follows: 

AGREEMENT 
 1. Unless
defined otherwise herein, capitalized terms used in this Amendment shall have the meanings given them in the Agreement. 
 2.
Section 4.4(a)(viii) shall be amended by replacing it in its entirety with the following: 
 (viii) [***] ($[***])
within thirty (30) days following the first approval in a Major Market by a Regulatory Authority of a Licensed Product for an additional Major Indication that a human cancer (each an “Additional Major Indication”). It is
understood that payments under this Section 4.4(a)(viii) shall be due for no more than three (3) Additional Major Indications, and, accordingly, the total amount due under this Section 4.4(a)(viii) shall not exceed [***] ($[***]).


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 










 3. Except as amended hereby, the Agreement shall continue in full force and effect in accordance
with its terms. 
 4. This Amendment shall be governed by and construed under the laws of the state of Washington without giving effect to
the principles of conflicts of laws. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 



  
 2 









 IN WITNESS WHEREOF, each of the parties has caused this Amendment to be executed by its duly
authorized representative. 
  

									
	CORIXA CORPORATION	  		 	INTROGEN THERAPEUTICS, INC.
					
	By:	 	 /s/ Mark McDade
	  		 	By:	 	 /s/ David L. Parker

	Name:	 	Mark McDade	  		 	Name:	 	David L. Parker
	Title:	 	President and COO	  		 	Title:	 	V.P. of Intellectual Property
				
	CHINOOK CORPORATION	  		 		 	
					
	By:	 	 /s/ Mark McDade
	  		 		 	
	Name:	 	Mark McDade	  		 		 	
	Title:	 	President